{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T18:05:41Z","timestamp":1761415541830,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"am","delay-in-days":394,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.hlc.2019.05.179","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T04:03:24Z","timestamp":1561003404000},"page":"824-834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prescribing Performance Post-Acute Coronary Syndrome Using a Composite Medication Indicator: ANZACS-QI 24"],"prefix":"10.1016","volume":"29","author":[{"given":"Chethan","family":"Kasargod","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerry","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mildred","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey D.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.hlc.2019.05.179_bib0005","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/1753-6405.12241","article-title":"Twenty-eight day and one-year case fatality after hospitalisation with an acute coronary syndrome: a nationwide data linkage study","volume":"38","author":"Grey","year":"2014","journal-title":"Aust N Z J Public Health"},{"issue":"8","key":"10.1016\/j.hlc.2019.05.179_bib0010","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.hlc.2016.03.004","article-title":"Ethnic differences in coronary revascularisation following an acute coronary syndrome in New Zealand: a national data-linkage study (ANZACS-QI 12)","volume":"25","author":"Grey","year":"2016","journal-title":"Heart Lung Circ"},{"issue":"1","key":"10.1016\/j.hlc.2019.05.179_bib0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/heartjnl-2017-311613","article-title":"First and recurrent ischaemic heart disease events continue to decline in New Zealand, 2005-2015","volume":"104","author":"Grey","year":"2018","journal-title":"Heart"},{"issue":"1357","key":"10.1016\/j.hlc.2019.05.179_bib0020","first-page":"122","article-title":"New Zealand 2012 guidelines for the management of non ST-elevation acute coronary syndromes","volume":"125","author":"Non ST-Elevation Acute Coronary Syndrome Guidelines Group and the New Zealand Branch of the Cardiac Society of Australia and New Zealand","year":"2012","journal-title":"N Z Med J"},{"issue":"1387","key":"10.1016\/j.hlc.2019.05.179_bib0025","article-title":"ST-elevation myocardial infarction: New Zealand Management Guidelines, 2013","volume":"126","author":"ST-Elevation Myocardial Infarction Guidelines Group and the New Zealand Branch of the Cardiac Society of Australia and New Zealand","year":"2013","journal-title":"N Z Med J"},{"issue":"7","key":"10.1016\/j.hlc.2019.05.179_bib0030","first-page":"e148","volume":"116","author":"Anderson","year":"2007","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.hlc.2019.05.179_bib0035","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.hlc.2016.06.789","article-title":"National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016","volume":"25","author":"Chew","year":"2016","journal-title":"Heart Lung Circ"},{"issue":"2","key":"10.1016\/j.hlc.2019.05.179_bib0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.hlc.2019.05.179_bib0045","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"issue":"9535","key":"10.1016\/j.hlc.2019.05.179_bib0050","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(06)69201-5","article-title":"Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials","volume":"368","author":"Dagenais","year":"2006","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.hlc.2019.05.179_bib0055","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/heartjnl-2013-304960","article-title":"Maintenance of statin use over 3 years following acute coronary syndromes: a national data linkage study (ANZACS-QI-2)","volume":"100","author":"Grey","year":"2014","journal-title":"Heart"},{"issue":"1400","key":"10.1016\/j.hlc.2019.05.179_bib0060","first-page":"39","article-title":"Effect of age, gender, ethnicity, socioeconomic status and region on dispensing of CVD secondary prevention medication in New Zealand: the Atlas of Health Care Variation CVD cohort (VIEW-1)","volume":"127","author":"Kerr","year":"2014","journal-title":"N Z Med J"},{"issue":"3","key":"10.1016\/j.hlc.2019.05.179_bib0065","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1071\/HC16013","article-title":"Initiation and maintenance of statins and aspirin after acute coronary syndromes (ANZACS-QI 11)","volume":"8","author":"Kerr","year":"2016","journal-title":"J Prim Health Care"},{"issue":"1439","key":"10.1016\/j.hlc.2019.05.179_bib0070","first-page":"23","article-title":"The all New Zealand acute coronary syndrome quality improvement programme: implementation, methodology and cohorts (ANZACS-QI 9)","volume":"129","author":"Kerr","year":"2016","journal-title":"N Z Med J"},{"year":"2004","series-title":"Ethnicity data protocols for the Health and Disability Sector","author":"Ministry of Health","key":"10.1016\/j.hlc.2019.05.179_bib0075"},{"issue":"16","key":"10.1016\/j.hlc.2019.05.179_bib0080","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","article-title":"Third universal definition of myocardial infarction","volume":"126","author":"Thygesen","year":"2012","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.hlc.2019.05.179_bib0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0002-9149(67)90023-9","article-title":"Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients","volume":"20","author":"Killip","year":"1967","journal-title":"Am J Cardiol"},{"issue":"7200","key":"10.1016\/j.hlc.2019.05.179_bib0090","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","article-title":"\u03b2-blockade after myocardial infarction: systematic review and meta regression analysis","volume":"318","author":"Freemantle","year":"1999","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.hlc.2019.05.179_bib0095","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jacc.2014.04.042","article-title":"Beta-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease","volume":"64","author":"Andersson","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.hlc.2019.05.179_bib0100","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"\u03b2-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.hlc.2019.05.179_bib0105","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1016\/j.jacc.2017.03.578","article-title":"\u03b2-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction","volume":"69","author":"Dondo","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.hlc.2019.05.179_bib0110","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jacc.2015.07.047","article-title":"Effect of beta-blocker dose on survival after acute myocardial infarction","volume":"66","author":"Goldberger","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.hlc.2019.05.179_bib0115","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.amjcard.2015.02.057","article-title":"Meta-analysis of relation between oral \u03b2-blocker therapy and outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention","volume":"115","author":"Huang","year":"2015","journal-title":"Am J Cardiol"},{"issue":"13","key":"10.1016\/j.hlc.2019.05.179_bib0120","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jacc.2017.07.783","article-title":"Adherence tradeoff to multiple preventive therapies and all-cause mortality after acute myocardial infarction","volume":"70","author":"Korhonen","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2019.05.179_bib0125","doi-asserted-by":"crossref","first-page":"i4801","DOI":"10.1136\/bmj.i4801","article-title":"\u03b2 blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study","volume":"354","author":"Puymirat","year":"2016","journal-title":"Br Med J"},{"issue":"25","key":"10.1016\/j.hlc.2019.05.179_bib0130","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: Executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hlc.2019.05.179_bib0135","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950619306018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950619306018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T18:02:04Z","timestamp":1761415324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950619306018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1443950619306018"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2019.05.179","relation":{},"ISSN":["1443-9506"],"issn-type":[{"type":"print","value":"1443-9506"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescribing Performance Post-Acute Coronary Syndrome Using a Composite Medication Indicator: ANZACS-QI 24","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2019.05.179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).","name":"copyright","label":"Copyright"}]}}